SPCC (Sharing Progress in Cancer Care) shared a post on LinkedIn:
“SPCC launches a new educational project on Minimal Residual Disease (MRD) in multiple myeloma
MRD is emerging as a powerful prognostic marker in multiple myeloma, offering insights beyond conventional response criteria. Its assessment is increasingly recognised for its ability to inform treatment decisions, guide therapeutic strategies, and support the evaluation of innovative approaches.
This project aims to provide clinicians with a clear and practical understanding of MRD, from detection methods to clinical data interpretation, supporting informed decision making and more personalised patient care.
Advisory and leadership team: Carl Ola Landgren (US), Bruno Paiva (ES), and Jesús San-Miguel (ES).
First webinar: “MRD in multiple myeloma: foundations and clinical relevance”
Wednesday, 11 February 2026 | 18:00 CET
Learn more about the project.
This activity is supported by an unrestricted medical contribution from Sanofi. Procedures for further independent support are ongoing.”
More from Sharing Progress in Cancer Care.